Subacute Invasive Aspergillosis Associated With Sorafenib Therapy for Hepatocellular Carcinoma.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

1. Aspergillus fumigatus and Aspergillosis in 2019.Clinical microbiology reviews · 2019
   Review
2. Fungal Infections with Ibrutinib and Other Small-Molecule Kinase Inhibitors.Current fungal infection reports · 2019
   Article
3. Reply to Bazaz and Denning.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2018
   Article

Corrections and comments

• Commented on by
  Reply to Bazaz and Denning.2018
• Comment on
  Call for Action: Invasive Fungal Infections Associated With Ibrutinib and Other Small Molecule Kinase Inhibitors Targeting Immune Signaling Pathways.2018

Authors and funding

2 authors at 2 institutions in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as